Publications by authors named "Benjamin A Yoder"
Article Synopsis
- This study investigates the effects of continuing osimertinib alongside platinum-pemetrexed chemotherapy for patients with EGFR mutant non-small cell lung cancer (NSCLC) who have had disease progression on osimertinib.
- It analyzed data from 159 eligible patients out of 421 identified, comparing outcomes between two groups: one continuing osimertinib with chemotherapy and the other receiving chemotherapy alone.
- Results showed that the group continuing osimertinib experienced a significant improvement in progression-free survival (9.0 months vs. 4.5 months), indicating a potential clinical benefit in this treatment strategy.
Introduction: Acquired gene amplification, exon 14 skip mutations, or fusions can emerge as resistance mechanisms to tyrosine kinase inhibitors (TKIs) in patients with lung cancer. The efficacy and safety of combining MET TKIs (such as crizotinib, capmatinib, or tepotinib) with parent TKIs to target acquired MET resistance are not well characterized.
Methods: Multi-institutional retrospective chart review identified 83 patients with metastatic oncogene-driven NSCLC that were separated into the following two pairwise matched cohorts: (1) MET cohort (n = 41)-patients with acquired MET resistance continuing their parent TKI with a MET TKI added or (2) Chemotherapy cohort (n = 42)-patients without any actionable resistance continuing their parent TKI with a platinum-pemetrexed added.